Focus On Biosimilars In Parathyroid Hormone Treatments For Enhanced Patient Care Trend: A Crucial Influence on the Parathyroid Hormone Market's Transformation in 2025

What Is the Expected Size and Growth Rate of the Parathyroid Hormone Market?
In recent times, the parathyroid hormone market has experienced consistent growth. Its size is projected to increase from $2.35 billion in 2024 to $2.43 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 3.5%. Factors contributing to this growth during the historic period include the escalating prevalence of chronic kidney disease, an enhanced understanding of disorders related to the parathyroid hormone, an increasing need for parathyroid hormone analogs, a surge in government funding for research on parathyroid hormone, and a rise in disposable incomes.

In the coming years, the parathyroid hormone market is predicted to experience robust growth. The estimated market size will reach $3.5 billion in 2029, with a compound annual growth rate (CAGR) of 9.6%. Factors contributing to this growth during the forecast period include the increasing geriatric demographic, the proliferation of private healthcare sectors, new indications, precision medicine, heightened awareness about bone health, and expanded healthcare access. The major trends during the forecast period are anticipated to be improvements in parathyroid hormone testing, enhanced drug delivery methods, combination therapies, the incorporation of digital health, and the implementation of sustainability and green practices.

What Factors Are Fueling Growth in the Parathyroid Hormone Market?
The escalating occurrence of osteoporosis is projected to be a catalyst for the parathyroid hormone market growth. Osteoporosis, a condition distinguished by reduced bone mass and bone tissue degradation, escalates the fracture risk. As an illustration, the International Osteoporosis Foundation reported in January 2023 that around 1.4 million Canadians, chiefly postmenopausal women and seniors, were suffering from osteoporosis. Parathyroid hormone, naturally synthesized by the body to balance calcium levels, is used to mitigate the probability of bone fracture in those with osteoporosis and is dispensed through a daily subcutaneous injection. Consequently, the amplification in osteoporosis cases is expected to fuel the expansion of the parathyroid hormone market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3427&type=smp

Which Leading Companies Are Shaping the Growth of the Parathyroid Hormone Market?
Major companies operating in the parathyroid hormone market include Pfizer Inc., Eli Lilly and Company, Radius Health Inc., Ascendis Pharma, Entera Bio Ltd., Extend Biosciences Inc., Gedeon Richter Plc., Abbott Laboratories, Amgen Inc., Merck & Co. Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Alcon Laboratories Inc., Bayer Healthcare, AstraZeneca PLC, Biocon, Dr. Reddy's Laboratories, Glenmark Pharmaceuticals, Jubilant Life Sciences, Lupin Limited, Sun Pharmaceutical Industries, Torrent Pharmaceuticals, Wockhardt, Cipla Limited

What Are the Major Trends Shaping the Parathyroid Hormone Market?
Leading firms in the parathyroid hormone market are investing in the development of biosimilars, like PTH prodrugs, which aim to improve therapeutic alternatives. These prodrugs, inactive variants of the parathyroid, become functionally active following their administration, allowing a long-lasting release and fostering consistent results for the regulation of calcium and bone health. As an example, Ascendis Pharma A/S, a biopharmaceutical company based in Denmark, received approval from the Food & Drug Administration (FDA) for YORVIPATH (palopegteriparatide) in August 2024. YORVIPATH is the first of its kind dedicated solely to the treatment of adult hypoparathyroidism. This once-daily administered prodrug provides constant PTH exposure and is estimated to benefit around 70,000 to 90,000 patients across the United States. Ascendis Pharma offers support to patients through its Ascendis Signature Access Program (A.S.A.P). However, those using the treatment are required to frequently check their serum calcium levels for potential hypercalcemia or hypocalcemia.

What Are the Key Segments of the Parathyroid Hormone Market?
The parathyroid hormone market covered in this report is segmented -

1) By Disease Type: Hypocalcemia, Hypoparathyroidism
2) By Product Type: Recombinant Parathyroid Hormone, Parathyroid Hormone Analogues
3) By End-User: Hospitals, Clinics, Other End-Users

Subsegments:
1) By Hypocalcemia: Pseudohypoparathyroidism, Vitamin D Deficiency
2) By Hypoparathyroidism: Post-Surgical Hypoparathyroidism, Idiopathic Hypoparathyroidism

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report

Which Region Dominates the Parathyroid Hormone Market?
The countries covered in the parathyroid hormone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

What Is Covered In The Parathyroid Hormone Global Market Report?

- Market Size Analysis: Analyze the Parathyroid Hormone Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Parathyroid Hormone Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Parathyroid Hormone Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Parathyroid Hormone Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3427

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.